Which medication combination is often prescribed as part of the discharge regimen after ACS?

The combination of beta-blockers and antiplatelet therapy is frequently part of the discharge regimen for patients after an acute coronary syndrome (ACS) event. Beta-blockers are essential in managing heart rate and reducing myocardial oxygen demand, which helps prevent further ischemic events. They also have a protective effect on the myocardium and can lower the risk of recurrent heart attacks.

Antiplatelet therapy, commonly in the form of aspirin or newer agents like clopidogrel, is crucial for preventing platelet aggregation and thrombus formation in patients who have experienced ACS. This significantly reduces the risk of subsequent cardiovascular events by preventing clot formation in the coronary arteries.

Together, these medications address the immediate risks associated with ACS and contribute to long-term cardiac protection, making this combination a standard part of discharge planning to improve outcomes for these patients.